Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
Share
Why It Matters
An analyst who watches Arcturus thinks the company looks more promising. They raised their target price from thirteen dollars to nineteen dollars.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.